Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Flow cytometric analysis of T-cell subsets and platelet surface markers in patients with immune thrombocytopenia: a case-control study.

Annals of hematology·2026
Same author

A Genetic and Biochemical Perspective: Acute Coronary Syndrome and Raftlin.

Journal of clinical medicine·2026
Same author

Prognostic Nutritional Index and In-Hospital Mortality After Coronary Artery Bypass Grafting: An Exploratory Analysis in Relation to Surgical Risk Scores.

Nutrients·2026
Same author

Effect of Clopidogrel on Early Inflammatory Response and In-Hospital Outcomes in Patients with Myocardial Infarction.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Elevated serum Raftlin levels in non-muscle invasive bladder cancer: diagnostic implications and rs690037 genotype analysis.

Revista da Associacao Medica Brasileira (1992)·2026
Same author

Prognostic Value of HALP and AHEAD Scores for Predicting 1-Month Heart Failure Following Myocardial Infarction.

Journal of clinical medicine·2026

Related Experiment Video

Updated: May 28, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Galectin-3 and Coronary Artery Disease: An Inflammation-Based Approach.

Rıdvan Bora1, Rojda Tanrıverdi2, Şenay Balcı Fidancı2

  • 1Department of Cardiology, Mersin City Education and Research Hospital, 33800 Mersin, Turkey.

Journal of Clinical Medicine
|May 27, 2026
PubMed
Summary

Elevated Galectin-3 levels indicate inflammation in coronary artery disease but do not reliably distinguish between acute and chronic coronary syndrome. Further research is needed to clarify its clinical value as a biomarker.

Keywords:
Galectin-3atherosclerosiscoronary artery diseaseinflammation

Related Experiment Videos

Last Updated: May 28, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Area of Science:

  • Cardiovascular Medicine
  • Biomarkers
  • Inflammation and Immunology

Background:

  • Coronary artery disease (CAD) is a chronic inflammatory condition involving atherosclerosis with varied clinical presentations.
  • Galectin-3, a protein involved in inflammation and fibrosis, is explored as a potential cardiovascular biomarker.
  • The diagnostic utility of Galectin-3 across different CAD stages is not well-established.

Purpose of the Study:

  • To investigate the diagnostic significance of serum Galectin-3 concentrations in patients with different clinical stages of coronary artery disease.
  • To evaluate Galectin-3 as a potential biomarker for distinguishing between acute coronary syndrome and chronic coronary syndrome.

Main Methods:

  • Prospective study of 180 participants undergoing coronary angiography, categorized into control, acute coronary syndrome, and chronic coronary syndrome groups.
  • Serum Galectin-3 levels measured via enzyme-linked immunosorbent assay.
  • Statistical analyses included non-parametric tests, correlation, receiver operating characteristic (ROC) curve analysis, and multivariable logistic regression.

Main Results:

  • Galectin-3 concentrations were significantly higher in both acute and chronic coronary syndrome groups compared to controls (p < 0.001).
  • No significant difference in Galectin-3 levels was found between acute and chronic coronary syndrome groups.
  • ROC analysis revealed limited diagnostic performance for Galectin-3 in identifying acute coronary syndrome (AUC 0.617) and poor performance for chronic coronary syndrome (AUC 0.541).
  • Galectin-3 was not an independent predictor; age and smoking predicted acute coronary syndrome, while age and male sex predicted chronic coronary syndrome.

Conclusions:

  • Elevated Galectin-3 levels in CAD patients reflect the inflammatory burden of atherosclerosis.
  • Galectin-3 shows limited ability to discriminate between acute and chronic coronary syndrome.
  • Larger prospective studies are necessary to determine the definitive clinical value of Galectin-3 in CAD management.